Jaguar Health, Inc. $(JAGX)$ has announced updates regarding their clinical development program for crofelemer, aimed at treating intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). The company is conducting two placebo-controlled Phase 2 studies in the United States, European Union, and Middle East/North Africa regions. Enrollment for the Phase 2 study on crofelemer's efficacy in pediatric MVID patients has reached approximately 25%, with completion expected in mid-2026. Additionally, enrollment for the SBS-IF study in adults has surpassed 10%. Initial proof-of-concept results from independent investigator-initiated trials indicate a reduction in required total parenteral nutrition for patients with MVID and SBS by up to 27% and 12.5%, respectively. Further data from these trials are anticipated as enrollment continues.